Free tool
FAERS Monitor: Amzeeq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212379 or its brand name (Amzeeq, Minocycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
11,701
Serious
8,940
76% of reports
Hospitalization
3,776
Death reported
1,645
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,981
- off label use1,488
- nausea1,077
- pain1,021
- arthralgia1,003
- fatigue962
- drug intolerance913
- rash910
- drug hypersensitivity907
- rheumatoid arthritis879
- joint swelling874
- headache804
- condition aggravated754
- diarrhoea752
- pneumonia750
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 52 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 79 |
| 2010 | 86 |
| 2011 | 99 |
| 2012 | 233 |
| 2013 | 416 |
| 2014 | 431 |
| 2015 | 539 |
| 2016 | 806 |
| 2017 | 871 |
| 2018 | 894 |
| 2019 | 1,144 |
| 2020 | 1,038 |
| 2021 | 780 |
| 2022 | 704 |
| 2023 | 882 |
| 2024 | 1,205 |
| 2025 | 974 |
| 2026 | 442 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,458 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug intoleranceSignal | 913 | 17.1 | 16.1 | 13,793 |
| rheumatoid arthritisSignal | 879 | 14.0 | 13.2 | 10,589 |
| joint swellingSignal | 874 | 13.1 | 12.3 | 9,744 |
| drug hypersensitivitySignal | 907 | 8.5 | 7.9 | 5,986 |
| condition aggravatedSignal | 754 | 4.5 | 4.2 | 2,050 |
| arthralgiaSignal | 1,003 | 4.3 | 4.1 | 2,624 |
| pneumoniaSignal | 750 | 4.2 | 3.9 | 1,829 |
| rashSignal | 910 | 3.8 | 3.5 | 1,874 |
| off label useSignal | 1,488 | 3.1 | 2.9 | 2,145 |
| painSignal | 1,021 | 3.0 | 2.8 | 1,390 |
| drug ineffectiveSignal | 1,981 | 2.7 | 2.6 | 2,265 |
| nauseaSignal | 1,077 | 2.4 | 2.3 | 956 |
| headacheSignal | 804 | 2.3 | 2.2 | 611 |
| fatigueSignal | 962 | 2.2 | 2.1 | 670 |
| diarrhoeaSignal | 752 | 2.1 | 2.0 | 443 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.